JP2019537576A5 - - Google Patents

Download PDF

Info

Publication number
JP2019537576A5
JP2019537576A5 JP2019522377A JP2019522377A JP2019537576A5 JP 2019537576 A5 JP2019537576 A5 JP 2019537576A5 JP 2019522377 A JP2019522377 A JP 2019522377A JP 2019522377 A JP2019522377 A JP 2019522377A JP 2019537576 A5 JP2019537576 A5 JP 2019537576A5
Authority
JP
Japan
Prior art keywords
aav
particle according
aav particle
disease
particles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019522377A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019537576A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/059986 external-priority patent/WO2018085688A1/en
Publication of JP2019537576A publication Critical patent/JP2019537576A/ja
Publication of JP2019537576A5 publication Critical patent/JP2019537576A5/ja
Priority to JP2022169285A priority Critical patent/JP2023002721A/ja
Pending legal-status Critical Current

Links

JP2019522377A 2016-11-04 2017-11-03 神経変性疾患を処置するための遺伝子移入用組成物、遺伝子導入法、及び遺伝子導入の使用 Pending JP2019537576A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022169285A JP2023002721A (ja) 2016-11-04 2022-10-21 神経変性疾患を処置するための遺伝子移入用組成物、遺伝子導入法、及び遺伝子導入の使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662418033P 2016-11-04 2016-11-04
US62/418,033 2016-11-04
PCT/US2017/059986 WO2018085688A1 (en) 2016-11-04 2017-11-03 Gene transfer compositions, methods and uses for treating neurodegenerative diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022169285A Division JP2023002721A (ja) 2016-11-04 2022-10-21 神経変性疾患を処置するための遺伝子移入用組成物、遺伝子導入法、及び遺伝子導入の使用

Publications (2)

Publication Number Publication Date
JP2019537576A JP2019537576A (ja) 2019-12-26
JP2019537576A5 true JP2019537576A5 (https=) 2020-12-03

Family

ID=62075988

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019522377A Pending JP2019537576A (ja) 2016-11-04 2017-11-03 神経変性疾患を処置するための遺伝子移入用組成物、遺伝子導入法、及び遺伝子導入の使用
JP2022169285A Pending JP2023002721A (ja) 2016-11-04 2022-10-21 神経変性疾患を処置するための遺伝子移入用組成物、遺伝子導入法、及び遺伝子導入の使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022169285A Pending JP2023002721A (ja) 2016-11-04 2022-10-21 神経変性疾患を処置するための遺伝子移入用組成物、遺伝子導入法、及び遺伝子導入の使用

Country Status (9)

Country Link
US (1) US20190269797A1 (https=)
EP (1) EP3534892A4 (https=)
JP (2) JP2019537576A (https=)
CN (1) CN110198712A (https=)
AU (1) AU2017355502B2 (https=)
BR (1) BR112019009074A2 (https=)
CA (1) CA3041548A1 (https=)
MX (1) MX2019005266A (https=)
WO (1) WO2018085688A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9818239B2 (en) 2015-08-20 2017-11-14 Zendrive, Inc. Method for smartphone-based accident detection
FI3635009T3 (fi) 2017-06-07 2026-04-07 Regeneron Pharma Koostumuksia ja menetelmiä entsyymien internalisoimiseksi
EP3698340A4 (en) 2017-10-20 2021-07-14 Zendrive, Inc. PROCEDURE AND SYSTEM FOR VEHICLE ASSOCIATED COMMUNICATION
JP7779653B2 (ja) 2018-02-07 2025-12-03 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 治療用タンパク質送達のための方法および組成物
EP3793591A1 (en) 2018-05-17 2021-03-24 Regeneron Pharmaceuticals, Inc. Anti-cd63 antibodies, conjugates, and uses thereof
WO2020068990A1 (en) 2018-09-26 2020-04-02 California Institute Of Technology Adeno-associated virus compositions for targeted gene therapy
EP3880235A4 (en) * 2018-11-14 2022-08-10 REGENXBIO Inc. GENE THERAPY OF NEURAL ZEROID LIPOFUSCINOSES
MX2021009250A (es) * 2019-02-01 2021-11-04 Spark Therapeutics Inc Metodos de tratamiento por vectores aav para la lipofuscinosis ceroidea neuronal infantil tardia tipo 2.
WO2021113475A1 (en) 2019-12-03 2021-06-10 Zendrive, Inc. Method and system for risk determination of a route
EP4118219A4 (en) * 2020-03-11 2024-04-17 Shanghai Belief-Delivery Biomed Co., Ltd. Novel use of aspirin compound in increasing nucleic acid expression
WO2025231406A1 (en) * 2024-05-02 2025-11-06 The Children's Hospital Of Philadelphia Methods to increase transduction of ependyma cells in brain

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070003518A1 (en) * 2002-04-19 2007-01-04 Atkinson Mark A Raav vector-based compositions and methods for the prevention and treatment of mammalian diseases
US20040258666A1 (en) * 2003-05-01 2004-12-23 Passini Marco A. Gene therapy for neurometabolic disorders
JPWO2005071085A1 (ja) * 2004-01-22 2007-09-06 株式会社ディナベック研究所 ウイルスベクターの製造方法
JP5706602B2 (ja) * 2006-02-08 2015-04-22 ジェンザイム・コーポレーション ニーマンピック病a型に対する遺伝子治療
PL3252161T3 (pl) * 2007-06-06 2022-03-07 Genzyme Corporation Terapia genowa dla lizosomalnych chorób spichrzeniowych
ES2745470T3 (es) * 2011-03-31 2020-03-02 Univ Iowa Res Found Partícula de AAV2 que comprende una proteína de la cápside de AAV2 y un vector que comprende un ácido nucleico que codifica una tripeptidilo peptidasa 1 (TPP1) para el tratamiento de lipofuscinosis ceroide infantil tardía (LINCL) en un mamífero no roedor mediante inyección intraventricular o administración icv
KR20240090694A (ko) * 2013-07-22 2024-06-21 더 칠드런스 호스피탈 오브 필라델피아 변종 aav 및 조성물, 세포, 기관 및 조직으로의 유전자 전이를 위한 방법 및 용도
EP3024497B1 (en) * 2013-07-26 2021-01-13 University of Iowa Research Foundation Methods and compositions for treating brain diseases
CN120174012A (zh) * 2013-10-24 2025-06-20 优尼科Ip有限公司 用于基因治疗神经疾病的aav-5假型载体
MX2016006584A (es) * 2013-11-20 2016-09-06 Univ Iowa Res Found Métodos y composiciones para tratar los depósitos de amiloide.
US20180236105A1 (en) * 2015-10-23 2018-08-23 University Of Iowa Research Foundation Methods for treating neurodegenerative diseases using gene therapy to delay disease onset and progression while providing cognitive protection
KR102719222B1 (ko) * 2017-05-11 2024-10-21 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 신경 세로이드 지질갈색소증에 대한 유전자 요법

Similar Documents

Publication Publication Date Title
JP2019537576A5 (https=)
Liu et al. Crossing the blood-brain barrier with AAV vectors
AU2023258448B2 (en) Adeno-associated virus vector
JP2019511570A5 (https=)
US20250360225A1 (en) Adeno-associated virus vector delivery of a fragment of micro-dystrophin to treat muscular dystrophy
JP2016503405A5 (https=)
JP2009526067A5 (https=)
JP2020519629A5 (https=)
RU2017115477A (ru) Полинуклеотиды aadc для лечения болезни паркинсона
IL299325B1 (en) Variants of acid alpha-glucosidase and their uses
JP2008540445A5 (https=)
JP2018506585A5 (https=)
IL273776B2 (en) Gene therapies for lysosomal disorders
JPWO2020106916A5 (https=)
JP2021533805A5 (https=)
JP2021525245A5 (https=)
IL263009B2 (en) Optimal clni genes and expression cassettes and their use
JP2021520811A5 (https=)
FI3373980T3 (fi) Menetelmiä lihasdystrofian hoitamiseksi
JP2023059858A5 (https=)
Ortolano et al. Present and future of adeno associated virus based gene therapy approaches
JPWO2020006458A5 (https=)
US20230277687A1 (en) Viral particles for use in treating tauopathies such as alzheimer's diseases by gene therapy
RU2019117062A (ru) Композиции, способы и применения переноса генов для лечения нейродегенеративных заболеваний
JPWO2019226832A5 (https=)